BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 26408719)

  • 1. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
    Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
    Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
    Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS
    Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma].
    Chmura A; Wojcieszek A; Mrochem J; Walaszek-Gruszka A; Deja R; Masłyk B; Bartnik W; Sodowski K
    Ginekol Pol; 2009 May; 80(5):361-6. PubMed ID: 19548456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
    Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
    Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC.
    Molina R; Torres MD; Moragas M; Filella X; Jo J; Giménez N; Traserra J; Ballesta AM
    Anticancer Res; 1995; 15(2):479-84. PubMed ID: 7763026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
    Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
    Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer.
    Wollenberg B; Jan V; Schmit UM; Hofmann K; Stieber P; Fateh-Moghadam A
    Anticancer Res; 1996; 16(5B):3117-24. PubMed ID: 8920778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck.
    Kandiloros D; Eleftheriadou A; Chalastras T; Kyriou L; Yiotakis I; Ferekidis E
    Med Oncol; 2006; 23(4):463-70. PubMed ID: 17303904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
    J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck.
    Ogawa T; Tsurusako Y; Kimura N; Nishioka S; Akagi H; Nishizaki K; Nishioka K; Rutka J
    Acta Otolaryngol Suppl; 1999; 540():72-6. PubMed ID: 10445084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.
    Kulpa J; Wójcik E; Radkowski A; Kolodziejski L; Stasik Z
    Anticancer Res; 2000; 20(6D):5035-40. PubMed ID: 11326663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
    Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
    Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
    Jiang AG; Chen HL; Lu HY
    BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
    Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
    Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Cyfra 21-1 and SCC assays in head and neck tumours.
    Banal A; Hacene K; Berthelot-Ruff E; Mahé E; Fontana X; Pichon MF
    Tumour Biol; 2001; 22(1):27-35. PubMed ID: 11054024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyfra 21.1, TPS and SCC in squamous cell carcinoma of larynx.
    Monteiro E; Varzim G; Crespo M; Araújo L
    An Otorrinolaringol Ibero Am; 2003; 30(5):467-79. PubMed ID: 14648927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma.
    Washino S; Hirai M; Matsuzaki A; Kobayashi Y
    Urol Int; 2011; 87(4):420-8. PubMed ID: 22041857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers.
    Shimada Y; Watanabe G; Kawamura J; Soma T; Okabe M; Ito T; Inoue H; Kondo M; Mori Y; Tanaka E; Imamura M
    Oncology; 2005; 68(2-3):285-92. PubMed ID: 16015046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.